X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bios3 (126) 126
humans (125) 125
index medicus (125) 125
oncology (121) 121
original reports (90) 90
female (69) 69
middle aged (65) 65
male (62) 62
aged (58) 58
treatment outcome (55) 55
adult (54) 54
disease-free survival (29) 29
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
kaplan-meier estimate (22) 22
aged, 80 and over (21) 21
adolescent (20) 20
cancer (20) 20
research design (20) 20
young adult (20) 20
chemotherapy (19) 19
antineoplastic agents - administration & dosage (18) 18
statistics in oncology (17) 17
neoplasm staging (16) 16
neoplasms - drug therapy (16) 16
survival rate (16) 16
time factors (16) 16
antineoplastic agents - adverse effects (15) 15
antineoplastic agents - therapeutic use (14) 14
neoplasms - therapy (14) 14
proportional hazards models (14) 14
to2 (14) 14
chemotherapy, adjuvant (13) 13
clinical-trials (13) 13
faze (13) 13
prognosis (13) 13
randomized controlled trials as topic (13) 13
bios4 (12) 12
breast-cancer (12) 12
clinical trials as topic (12) 12
therapy (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (11) 11
carcinoma (11) 11
drug administration schedule (11) 11
risk factors (11) 11
survival analysis (11) 11
combined modality therapy (10) 10
dose-response relationship, drug (10) 10
solid tumors (10) 10
carcinoma, non-small-cell lung - pathology (9) 9
cell lung-cancer (9) 9
clinical trials, phase iii as topic (9) 9
disease progression (9) 9
follow-up studies (9) 9
phase-ii (9) 9
stat (9) 9
survival (9) 9
united states (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
breast neoplasms - drug therapy (8) 8
cisplatin - administration & dosage (8) 8
clinical trials, phase ii as topic (8) 8
lung neoplasms - pathology (8) 8
maximum tolerated dose (8) 8
neoplasms - pathology (8) 8
patient selection (8) 8
prospective studies (8) 8
breast neoplasms - therapy (7) 7
child (7) 7
doxorubicin - administration & dosage (7) 7
end-points (7) 7
etoposide - administration & dosage (7) 7
expression (7) 7
follow-up (7) 7
lung neoplasms - drug therapy (7) 7
metastatic colorectal-cancer (7) 7
neur1 (7) 7
predictive value of tests (7) 7
randomized controlled trials as topic - methods (7) 7
recurrence (7) 7
retrospective studies (7) 7
risk (7) 7
trial (7) 7
breast neoplasms - mortality (6) 6
cells (6) 6
chemoradiotherapy (6) 6
clinical trials as topic - methods (6) 6
combination (6) 6
hema5 (6) 6
lung neoplasms - mortality (6) 6
mutation (6) 6
adjuvant chemotherapy (5) 5
age factors (5) 5
antineoplastic agents - pharmacokinetics (5) 5
bc5 (5) 5
bc7 (5) 5
bc8 (5) 5
biomarkers, tumor - analysis (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
chronic myelogenous leukemia (5) 5
clinical trials, phase i as topic - methods (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Index Medicus | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 36, pp. 4284 - 4292
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2015, Volume 33, Issue 1, pp. 74 - 82
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2016, Volume 34, Issue 17, pp. 2020 - 2027
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 33, pp. 4148 - 4154
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2014, Volume 32, Issue 34, pp. 3858 - 3867
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 24, pp. 4027 - 4034
Purpose Biomarkers can add substantial value to current medical practice by providing an integrated approach to prediction using the genetic makeup of the... 
CELL LUNG-CANCER | POSITIVE BREAST-CANCER | ADJUVANT CHEMOTHERAPY | GROWTH-FACTOR RECEPTOR | SURVIVAL BENEFIT | ONCOLOGY | COLORECTAL-CANCER | PHASE-III | MINDACT TRIAL | GENE COPY NUMBER | GEFITINIB IRESSA | Clinical Trials as Topic | Retrospective Studies | Prospective Studies | Biomarkers, Tumor | Research Design | Humans | Index Medicus | To2 | Bios3 | Statistics in Oncology
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2009, Volume 27, Issue 19, pp. 3133 - 3140
Journal Article